2020-004494-41: This is a study that will evaluate the safety and efficacy of TOOKAD® (padeliporfin) Vascular Targeted Photodynamic Therapy (VTP) in the Treatment of Low Grade Upper Tract Urothelial Cancer (UTUC). |
|
|
| Not yet recruiting | 3 | 100 | Europe | TOOKAD®, [PRD5572518], Powder for solution for injection, TOOKAD® | Steba Biotech S.A., STEBA BIOTECH S.A., Steba biotech, S.A., Steba Biotech, S.A., Steba Biotech S.A., Steba Biotech, S.A., Steba biotech, S.A. | Low Grade Upper Tract Urothelial Cancer, Urinary tract cancers, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 3 | 100 | Europe, US, RoW | padeliporfin VTP, WST11 | Steba Biotech S.A., PrimeVigilance, ICON plc | Transitional Cell Cancer of Renal Pelvis and Ureter | 12/24 | 01/29 | | |